By Fineline Cube 
Triastek (Nanjing) Pharmaceutical Technology Co., Ltd. (“Triastek”) announced the completion of a new strategic financing round, with investors including Shanghai Minhang District Financial Investment Development Co., Ltd., Shanghai Lingang Digital Science Private Equity Fund Management Co., Ltd., and other strategic partners.
Financing Details
| Component | Detail |
|---|---|
| Company | Triastek (Nanjing) Pharmaceutical Technology Co., Ltd. |
| Financing Type | Strategic investment round |
| Lead Investors | Shanghai Minhang District Financial Investment Development Co., Ltd.; Shanghai Lingang Digital Science Private Equity Fund Management Co., Ltd. |
| Announcement Date | 13 Jul 2026 |
| Fund Allocation | Shanghai International R&D and Manufacturing Center construction; oral peptide pipeline clinical advancement; international cooperation expansion |
| Company Founded | 2015 |
This strategic financing represents significant validation of Triastek’s proprietary 3D printing pharmaceutical technology and positions the company for accelerated global expansion.
Proprietary Technology Platform
- Core Technology: Melt Extrusion Deposition (MED) 3D printing pharmaceutical technology
- Platform Count: Five distinct 3D microstructure drug delivery platforms
- Technology Applications:
- Modified release formulations
- Solubility enhancement systems
- Intestinal targeting delivery
- Gastric retention mechanisms
- Oral biologics delivery
Triastek’s MED technology enables precise control over drug release profiles and bioavailability through sophisticated 3D microstructure design, addressing key challenges in oral drug delivery particularly for peptides and other complex molecules.
Strategic Investment Allocation
Shanghai International R&D and Manufacturing Center
- Location: Shanghai (strategic hub for pharmaceutical innovation)
- Purpose: Integrated research, development, and manufacturing facility
- Capacity: Scalable GMP-compliant production capabilities
- Timeline: Construction to commence immediately post-financing
Oral Peptide Pipeline Advancement
- Focus Area: Clinical development of 3D-printed oral peptide therapeutics
- Technology Advantage: Overcoming traditional barriers to oral peptide delivery
- Pipeline Status: Multiple candidates in preclinical and early clinical stages
- Therapeutic Areas: Metabolic diseases, oncology, and other high-value indications
International Cooperation Expansion
- Geographic Focus: Global partnerships and market access initiatives
- Partnership Types: Licensing agreements, co-development collaborations, and commercial partnerships
- Strategic Rationale: Leverage proprietary technology for international market penetration
Market Context & Competitive Positioning
| Aspect | Traditional Approaches | Triastek’s 3D Printing Advantage |
|---|---|---|
| Drug Delivery Precision | Limited control over release kinetics | Precise microstructure engineering |
| Oral Bioavailability | Poor for peptides and complex molecules | Enhanced through targeted delivery systems |
| Manufacturing Flexibility | Batch-based, limited customization | On-demand, patient-specific production potential |
| IP Protection | Generic competition risk | Strong proprietary technology moat |
The global 3D printed pharmaceuticals market is projected to reach $1.2 billion by 2030, driven by demand for personalized medicine and advanced drug delivery solutions.
Investor Profile & Strategic Rationale
Shanghai Minhang District Financial Investment Development Co., Ltd.
- Investment Focus: Local economic development and high-tech industry support
- Strategic Alignment: Strengthening Shanghai’s pharmaceutical innovation ecosystem
Shanghai Lingang Digital Science Private Equity Fund Management Co., Ltd.
- Investment Focus: Digital science and advanced manufacturing technologies
- Strategic Alignment: Supporting cutting-edge pharmaceutical manufacturing innovation
The participation of government-backed and specialized digital science investors validates Triastek’s position at the intersection of pharmaceutical science and advanced manufacturing technology.
Company Milestones & Pipeline Progress
- Founded: 2015
- Technology Development: Proprietary MED 3D printing platform established
- Platform Diversification: Five complementary drug delivery platforms operational
- Pipeline Development: Multiple 3D printed drug product candidates in development
- Current Focus: Oral peptide therapeutics as flagship application area
Triastek has successfully demonstrated proof-of-concept for its technology across multiple therapeutic areas, with oral peptides representing the most promising near-term commercial opportunity.
Strategic Implications
- Technology Leadership: Establishes Triastek as pioneer in pharmaceutical 3D printing applications
- Manufacturing Innovation: Positions company to disrupt traditional pharmaceutical manufacturing paradigms
- Global Expansion: Strategic financing enables international regulatory filings and partnership development
- Pipeline Acceleration: Clinical advancement of oral peptide candidates on expedited timeline
- Infrastructure Development: Shanghai facility will serve as global headquarters and manufacturing hub
Forward‑Looking Statements
This brief contains forward-looking statements regarding development timelines, regulatory approvals, and commercial expectations. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption of novel manufacturing technologies.-Fineline Info & Tech